Ignite Creation Date:
2025-12-25 @ 4:41 AM
Ignite Modification Date:
2025-12-26 @ 3:42 AM
Study NCT ID:
NCT00379418
Status:
COMPLETED
Last Update Posted:
2013-09-12
First Post:
2006-09-19
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Anti Ischemic Effects of Abciximab in Angioplasty and Stenting Patients
Sponsor:
Emory University
Organization:
Study Overview
Official Title:
Anti Ischemic Effects of Abciximab in Angioplasty and Stenting Patients (AIR)
Status:
COMPLETED
Status Verified Date:
2013-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
AIR
Brief Summary:
AIR STUDY
TITLE: Anti-Ischemic effects of Abciximab(Reopro)
PATIENT POPULATION: Patients undergoing PCI(an interventional procedure placing a small stent/metallic tube to keep a narrowed artery in your heart open) and either on a stable statin dose or not on a statin. Statin= cholesterol lowering drug(ie, lipitor, zocor).
INTERVENTION: Heparin vs. heparin + abciximab during PCI
PURPOSE: Measure the effects of abciximab on special healing blood stem cells (EPC's-Endothelial Progenitor Cells), on inflammation, on oxidative stress and on microvascular blood flow.
PATIENT ASSESSMENT:
1. 50ccs blood draw on day 1(from sheath), day 2 ,day 7 and day 28.
2. Measurement of blood flow in selected suitable patients
3. 10 minute questionnaire before discharge and on visit on day 28.
TITLE: Anti-Ischemic effects of Abciximab(Reopro)
PATIENT POPULATION: Patients undergoing PCI(an interventional procedure placing a small stent/metallic tube to keep a narrowed artery in your heart open) and either on a stable statin dose or not on a statin. Statin= cholesterol lowering drug(ie, lipitor, zocor).
INTERVENTION: Heparin vs. heparin + abciximab during PCI
PURPOSE: Measure the effects of abciximab on special healing blood stem cells (EPC's-Endothelial Progenitor Cells), on inflammation, on oxidative stress and on microvascular blood flow.
PATIENT ASSESSMENT:
1. 50ccs blood draw on day 1(from sheath), day 2 ,day 7 and day 28.
2. Measurement of blood flow in selected suitable patients
3. 10 minute questionnaire before discharge and on visit on day 28.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: